Phase-Transitioning Ocular Implant for Controlled and Unidirectional Retinal Gene Therapy
This invention is a novel, polymer-based implant designed to deliver therapeutic agents, such as viral vectors for gene therapy, directly and safely to the retina. Its key advantage is the ability to maintain physical properties that ensure safe placement and provide controlled, unidirectional release of the agent to the desired region of the eye, preventing unwanted diffusion into the vitreous.
Description
The core of the technology is a polymer component capable of undergoing sequential phase transitions when exposed to the aqueous environment of the eye, such as the vitreous. The implant is initially a dehydrated, opaque solid that transitions first into a transparent gel-like phase and finally dissolves into a liquid phase over a controlled period. The therapeutic agent is primarily released while the material is in the stable gel phase, ensuring controlled and timely delivery. A critical, innovative feature is the inclusion of an optional semi-permeable or fully impermeable backing layer on one surface of the implant. This backing layer is strategically engineered to block therapeutic agent diffusion in one direction, thereby directing the release solely toward the retinal tissue and away from the vitreous body. This localized delivery minimizes the risk of off-target effects and improves the efficacy of the treatment, especially for potent agents like gene therapy vectors.Applications
- Retinal Gene Therapy: Ideal delivery platform for viral vectors, such as adeno-associated virus (AAV), to treat inherited or acquired retinal disorders.- Treatment of Macular Diseases: Application in treating diseases affecting the macula, such as inherited macular degeneration and Stargardt disease.
- Diabetic Retinopathy: A potential new method for administering therapeutics to combat diabetic retinopathy, including the proliferative form.
- Ocular Vascular Diseases: Treatment for conditions like central retinal vein occlusion and retinal arterial occlusive disease.
- Retinitis Pigmentosa: Targeted drug delivery for inherited vision loss conditions, including X-linked retinitis pigmentosa.
Advantages
- Targeted Delivery: Enables controlled and timely release of the therapeutic agent directly to the retina, maximizing local drug concentration.- Unidirectional Efficacy: The optional backing layer promotes one-way diffusion, significantly reducing undesired drug diffusion into the vitreous and improving treatment precision.
- Eliminates Removal: The polymer component dissolves completely into a liquid phase, which can eliminate the need for a secondary surgical procedure to remove the device.
- Enhanced Safety: The solid form, which becomes a transparent gel upon hydration, ensures safe placement in the ocular region.
- Vector Protection: Avoids the high rates of inactivation seen when therapeutic vectors are administered by diffusing them through the vitreous.